Evidence map›Paper›PMID 39936427›Full record

ArticleCurrent pharmaceutical design2025

Biological Evaluation and Computational Modelling Studies on

Betul Giray, Nil Kaya, Martina Fiabane, Ayse Seyma Buyuk, Hatice Başpinar Kucuk, Semra Sardas, Mattia Mori

Abstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Betul GirayDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Istinye University, 34010, Istanbul, Türkiye.
Nil KayaDepartment of Pharmaceutical Microbiology, Faculty of Pharmacy, Istinye University, 34010, Istanbul, Türkiye.
Martina FiabaneDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100, Siena, Italy.
Ayse Seyma BuyukDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Istanbul University-Cerrahpaşa, 34500, Istanbul, Türkiye.
Hatice Başpinar KucukDepartment of Chemistry, Organic Chemistry Division, Faculty of Engineering, Istanbul University-Cerrahpasa, 34010, Istanbul, Türkiye.
Semra SardasDepartment of Pharmaceutical Toxicology, Faculty of Pharmacy, Istinye University, 34010, Istanbul, Türkiye.
Mattia MoriDepartment of Biotechnology, Chemistry, and Pharmacy, University of Siena, 53100, Siena, Italy.

Funding

COST (European Cooperation in Science and Technology) CA21145Istanbul University-Cerrahpasa Scientific Research Projects FBA-2023-37327NextGeneration EU-MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases PE00000007
6 · The paper itself

Abstract

introductionThe increasing use of antibiotics coupled with the lack of innovative and effective antimicrobial agents has increased the development of antimicrobial resistance (AMR) worldwide. To overcome the AMR-associated prolonged disease duration and increased mortality rates, new antimicrobial agents are in high demand. In this context, hydrazone and oxadiazole derivatives are endowed with remarkable biocidal activity, becoming profitable scaffolds in the design of antimicrobial candidates.

methodsIn this study, the antimicrobial effects of N-acyl hydrazones 1-15 and 2,5-disubstituted 1,3,4- oxadiazoles 16-27 against

resultsFinally, molecular docking and dynamics (MD) studies identified four compounds as potential inhibitors of bacterial DNA gyrase B (GyrB).

conclusionFurther exploration of molecular determinants revealed favourable drug-like properties, highlighting the potential of these molecules for subsequent hit-to-lead optimization studies.

Indexed as

Anti-Bacterial AgentsAntifungal AgentsAnti-Infective AgentsHydrazonesOxadiazolesBacteriaCandida albicansEscherichia coliMicrobial Sensitivity TestsMolecular Docking SimulationMolecular StructureStructure-Activity Relationship1,3,4-oxadiazoleAnti-Bacterial AgentsAntifungal AgentsAnti-Infective AgentsHydrazonesOxadiazolesantimicrobial activityantimicrobial resistancebacterial DNA gyraseESKAPEHydrazonestetracyclines.

Identifiers

PMID39936427

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.